Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thrombolytic Science International LLC

Novel clot-dissolving drug for ischemic stroke

This article was originally published in Start Up

Executive Summary

Thrombolytic Science International LLC’s drug candidate for acute post-stroke therapy is a mutant of pro-urokinase, a natural enzyme found in humans that, like tPA, also activates plasmin. TSI’s modified protein is designed to hold its inert, pro-enzymatic form longer in the bloodstream, enabling it to retain its occlusive clot specificity at higher, therapeutic doses with reduced risk of bleeding.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts